Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 6/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | TERT | O14746 | 1/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1672720 | 0.82 | SLC5A2 (0.38) | SLC5A2HTR1ASLC6A4POLBSLC5A1 | |
| SCHEMBL12806098 | 0.82 | CYP2D6 (0.38) | SLC5A2SLC6A4SLC5A1CYP2D6TERT | |
| SCHEMBL16560455 | 0.82 | SLC5A2 (0.53) | SLC5A2SLC5A1 | |
| SCHEMBL1670204 | 0.81 | ALDH1A1 (0.43) | SLC5A2POLBMAPT | |
| SCHEMBL28570770 | 0.81 | SLC5A1 (0.53) | SLC5A2SLC5A1 | |
| SCHEMBL1670175 | 0.75 | CYP2D6 (0.39) | MAPTCYP2D6 | |
| SCHEMBL10341 | 0.73 | LMNA (0.48) | POLBLMNAMAPTHTTBLM | |
| SCHEMBL29413018 | 0.73 | LMNA (0.48) | POLBLMNAMAPTHTTBLM | |
| SCHEMBL13470507 | 0.72 | SNCA (0.67) | HTR1AMAPTCYP2D6 | |
| SCHEMBL13278770 | 0.72 | SLC5A2 (0.64) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49080-E1 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2022-05-24 | — | — | US | disclosed |
| CN-108203432-B | Glucopyranosyl derivative and application thereof in medicine | 宜昌东阳光长江药业股份有限公司 | 2021-03-02 | — | — | CN | disclosed |
| EP-3056507-B1 | C-ARYL GLUCOSIDE DERIVATIVE, PREPARATION METHOD FOR SAME, AND MEDICAL APPLICATIONS THEREOF | YOUNGENE THERAPEUTICS CO LTD (CN) | 2020-09-23 | — | — | EP | disclosed |
| EP-3056507-B1 | C-ARYL GLUCOSIDE DERIVATIVE, PREPARATION METHOD FOR SAME, AND MEDICAL APPLICATIONS THEREOF | YOUNGENE THERAPEUTICS CO LTD (CN) | 2020-09-23 | — | — | EP | disclosed |
| US-10011627-B2 | C-aryl glucoside derivative, preparation methods thereof, and medical applications thereof | YOUNGENE THERAPEUTICS CO., LTD (CN) | 2018-07-03 | — | — | US | disclosed |
| US-10011627-B2 | C-aryl glucoside derivative, preparation methods thereof, and medical applications thereof | YOUNGENE THERAPEUTICS CO., LTD (CN) | 2018-07-03 | — | — | US | disclosed |
| US-9895389-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2018-02-20 | — | — | US | disclosed |
| US-9895389-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2018-02-20 | — | — | US | disclosed |
| US-20170042925-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2017-02-16 | — | — | US | disclosed |
| US-20170042925-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2017-02-16 | — | — | US | disclosed |
| US-20120178680-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2012-07-12 | — | — | US | disclosed |
| US-20120178680-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2012-07-12 | — | — | US | disclosed |
| US-20120178680-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2012-07-12 | — | — | US | disclosed |
| US-8163704-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | disclosed |
| US-8163704-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | disclosed |
| US-8163704-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | disclosed |
| US-20110171159-A1 | Glycoside Derivatives and Uses Thereof | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| US-20110171159-A1 | Glycoside Derivatives and Uses Thereof | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| US-20110171159-A1 | Glycoside Derivatives and Uses Thereof | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| WO-2011048112-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170042925-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885HTR1A 3802/4885SLC6A4 126/4885 |
| US-20120178680-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885HTR1A 3802/4885SLC6A4 126/4885 |
| US-10011627-B2 | C-aryl glucoside derivative, preparation methods thereof, and medical applications thereof | SLC5A1, SLC5A2, UGGT1 | SLC5A2 2/4885HTR1A 1295/4885SLC6A4 65/4885 |
| US-20110171159-A1 | Glycoside Derivatives and Uses Thereof | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885HTR1A 3802/4885SLC6A4 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.